Table of contents
Trial overview
The available trial data describe one authorised interventional study of Levodropropizine in people with dyspnea, which means shortness of breath.[1]
The study is titled INFURO and it examines the impact of inhaled furosemide and orally administered Levodropropizine on dyspnea perception in patients with advanced respiratory diseases.[1]
Who is being studied
This trial targets patients with advanced lung disease and dyspnea, so the study population has serious breathing problems related to respiratory illness.[1]
The planned enrollment is 114 participants, which means the researchers plan to include 114 people in the study.[1]
Study design and phase
This is a Phase 2 trial, a stage that usually looks for early signs of benefit while continuing safety checks in a defined patient group.[1]
The study status is Authorised, which means it has received permission to proceed according to the source data.[1]
The intervention plan includes oral use of Levodropropizine, along with inhaled furosemide and sodium chloride inhalation as listed in the trial record.[1]
What is being measured
The main outcome is safety and tolerability of a single dose of inhaled furosemide, measured by the number and type of treatment-related adverse events.[1]
The study also focuses on dyspnea perception, meaning how patients feel or notice their shortness of breath during the study.[1]
Trial details
The trial record lists three interventions: sodium chloride by inhalation, furosemide by inhalation, and Levodropropizine by mouth.[1]
Because the source data provide only one trial, the current clinical research picture for Levodropropizine in this set is limited to this single Phase 2 study in advanced respiratory disease.[1]
